WATERTOWN, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the pricing of an underwritten public offering of 10,526,500 shares of its common stock at a public offering price of $1.90 per share. The gross proceeds of the offering to the Company are expected to be approximately $20 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty day option to purchase up to an additional 1,578,975 shares of common stock at the public offering price, less underwriting discounts and commissions.

The closing of the offering is expected to occur on or about April 1, 2019, subject to the satisfaction of customary closing conditions.

Guggenheim Securities is acting as sole book-running manager for the offering. H.C. Wainwright & Co. and Laidlaw & Company (UK) Ltd. are acting as co-managers for the offering.

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) (www.eyepointpharma.com), headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has two products, YUTIQ™ and DEXYCU™, that were approved by the U.S. Food and Drug Administration in 2018 and have been launched directly in the U.S. during the first quarter of 2019.